Skip Navigation

Annals of Oncology 2009 20(4):605-608; doi:10.1093/annonc/mdp203
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wong, R.
Right arrow Articles by Cunningham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, R.
Right arrow Articles by Cunningham, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

editorial

Optimising treatment regimens for the management of advanced gastric cancer

R. Wong and D. Cunningham*

Royal Marsden Hospital, Sutton, Surrey, UK

* (E-mail: david.cunningham@rmh.nhs.uk)

The first 150 words of the full text of this article appear below.

Systemic chemotherapy for advanced gastric cancer (AGC) has been demonstrated to improve survival and quality of life compared with best supportive care and is routinely offered to patients of adequate performance status (PS) [1, 2]. Combination chemotherapy results in superior outcomes compared with monotherapy [2] and several large randomised controlled trials have been conducted over the past few decades in an attempt to define the optimal first-line regimen. Despite this, to date no chemotherapy regimen has been universally accepted as standard first-line therapy for AGC. Unresolved issues include which drug combinations are best to use upfront, triplet versus doublet therapy, and whether results can be translated between Eastern and Western populations. Additionally, results of recent trials have reinforced the importance of careful patient selection in order to minimise treatment-related toxicity, precipitating the evaluation of treatment options with more favourable toxicity profiles and with more convenient . . . [Full Text of this Article]

funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. R. Lord, P. S. Hall, and M. T. Seymour
Are we representing the true population in oncology trials?
Ann. Onc., December 1, 2009; 20(12): 2022 - 2022.
[Full Text] [PDF]